Platelet-Rich Plasma for Hair Loss: Update and Expert Q&A
According to estimates from the National Institutes of Health, androgenic alopecia affects 30 million women and 50 million men in the United States.
Hair And Scalp
Rapid Therapeutic Effect in Alopecia Areata Seen With JAK3, TYK2, and JAK1 Inhibitors
PF-06700841 and PF-06651600 were found to have an effect onset of 6 and 4 weeks, respectively in patients with moderate to severe alopecia areata.
Subcutaneous Dupilumab Initiates Hair Regrowth in Patient With Alopecia Totalis, Atopic Dermatitis
Dupilumab, commonly used for eczema, may be effective for hair regrowth in patients with alopecia totalis and atopic dermatitis.
Low-Dose Ruxolitinib May Promote Hair Regrowth in Severe Alopecia
Complete or near-complete hair regrowth occurred in 5 patients, with a 98% improvement in the Severity of Alopecia Tool score.
Disease Extent, Nail Involvement May Predict Clinical Outcomes of Contact Immunotherapy for Alopecia Areata
Hair growth outcomes with contact immunotherapy for alopecia areata were associated with many factors and there was a significant variability in the criteria used.
Mental Health Hospitalizations in Patients With Alopecia Areata
Patients with alopecia areata may have multiple risk factors for mental health disorders, including psychological distress and impaired quality of life.
Endocrine Therapy-Induced Alopecia Seen in Breast Cancer
For patients with breast cancer, endocrine therapy-induced alopecia has a pattern that is similar to androgenetic alopecia.
Alopecia Areata Has Significant Effect on Quality of Life in Adult, Pediatric Patients
Patients were most often affected by feelings of embarrassment and self-consciousness, followed by effects on social and leisure activities.
Alopecia Effectively Treated With Carboxytherapy
Carboxytherapy is a promising therapeutic treatment option for patchy alopecia areata and could be used as an adjuvant therapy of androgenetic alopecia.
FDA Fast-Tracks Alopecia Areata Treatment
The FDA has granted Fast Track designation for CTP-543, a novel oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata, which currently has no approved treatments.
Next post in General Dermatology
